Navigation Links
YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Date:2/13/2009

MISSISSAUGA, ON, Feb. 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported operational and financial results for the second quarter of fiscal 2009, ended December 31, 2008.

"During the quarter we prepared to initiate our two randomized Phase II trials for nimotuzumab, which concentrate on two forms of cancer typically treated with radiation-containing regimens. These trials are the cornerstone of YM's registration program for this drug, driven by prior data indicating nimotuzumab's potential to maximize the benefits of radiotherapy while avoiding the toxic side-effects of the other EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "In addition to YM's internal clinical strategy, we continue to benefit from the network of cooperative relationships for the development of nimotuzumab which is undertaking a broad, late-stage, clinical program for this drug."

    Highlights for the second quarter of Fiscal 2009:

    -   YM received clearance from Canadian regulatory authorities to
        initiate two Phase II, double-blind, randomized trials for its EGFR-
        targeting antibody, nimotuzumab, in combination with radiation-based
        treatments. Enrolment for both trials, one in patients with non-small
        cell lung cancer (NSCLC) and the other in patients with brain
        metastases from NSCLC, is expected to be initiated in Canada in the
        first quarter of calendar 2009 and YM anticipates expanding the
        trials into other countries.
    -   The National Cancer Centre of Singapore (NCCS) selected nimotuzumab
        for evaluation in the adjuvant setting in a multinational Phase III
        trial of more than 700 patients with cancers of the head and neck,
        citing the drug's preferential safety profil
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
2. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
3. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
5. BD Biosciences to Distribute FCS Express
6. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
7. Cell Biosciences Introduces Kits for Oncoprotein Analysis
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NY (PRWEB) July 26, 2014 ... Review, H2, 2014" provides data on the Ischemic ... report provides elemental information and data relating to ... Stroke. , View full global Ischemic Stroke Research ... includes an overview of the trial numbers and ...
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... approved a $500,000 start-up grant for the recently ... for classified, defense-related projects. , ,The consortium, ... initially include the UW System, the Medical College ... the Milwaukee School of Engineering. , ,The consortium ...
... Cisco Systems has reached an agreement ... local area network. , ,The UW-Madison campus serves 41,500 ... includes more than 180 buildings spread across 933 acres. ... can access a personalized window of their financial records, ...
... tiny man with giant ideas. Ill never forget the one and ... a conference of business executives in Cambridge, Massachusetts. There were one ... for a keynote, Drucker spoke immediately after lunch. He had to ... effortlessly for almost two hours. No Powerpoint. No props. No nonsense. ...
Cached Biology Technology:Wisconsin consortium aims for defense business 2Praise for the principles of Peter 2Praise for the principles of Peter 3Praise for the principles of Peter 4
(Date:7/28/2014)... Research Hospital study found that 73 percent of adult ... of developing metabolic syndrome and related health problems by ... in the current issue of the journal Cancer ... survivors of childhood cancer in the study had metabolic ... high blood pressure, abdominal obesity, elevated triglyceride and other ...
(Date:7/28/2014)... Brain & Behavior Research Foundation today announced the ... recognizing exceptional clinical and basic research by young ... Investigator Grants. The grants enable early career scientists ... research for the prevention, early detection, treatment, and ... four people. , Six young scientistswinners of the ...
(Date:7/28/2014)... Research and Markets has announced ... America 2014-2018" report to their offering. ... and analyze biological data. These systems capture biological traits ... patterns, and hand measurements from the subject and compare ... main purpose of a biometrics system is to identify ...
Breaking Biology News(10 mins):Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Biometrics Market in Latin America 2014-2018 2
... PLoS ONE highlights how the exploration of the ... of a voyage of discovery, starting with marine animals ... their application as marker in living cells. Many ... fluorescent proteins, which come in a variety of dazzling ...
... 30 Orchid Cellmark Inc.,(Nasdaq: ORCH ), a leading ... for the third quarter of 2008. , ... of 2008 compared,to $15.6 million for the third quarter of 2007. ... compared to a year ago was largely due,to lower revenues in ...
... 10 prominent scientists says that the level of globe-warming carbon ... where world climate will change disastrously unless the level can ... from recent estimates that truly dangerous levels would be reached ... the current edition of the Open Atmospheric Science Journal ...
Cached Biology News:Biomedical research profits from the exploration of the deep sea 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Carbon dioxide already in danger zone, warns study 2
...
The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
... in this set of Antibody Microarray ... for a total of over 2100 ... internal control. Antibodies belonging to many ... cell cycle progression, signal transduction and ...
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
Biology Products: